Vimarsana
Biggest News Aggregation in the World

Page 8 - Small Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Small Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Small Cell Today - Breaking & Trending Today

AccelerComm, Radisys, RFDSP and TTP Partnership Offers 5G LEO Regenerative Base Station Solution to Deliver High-Performance Cellular Service from Space - Vimarsana News

AccelerComm, Radisys, RFDSP and TTP Partnership Offers 5G LEO Regenerative Base Station Solution to Deliver High-Performance Cellular Service from Space

Companies unveil a LEO Regenerative 5G RAN reference solution architecture. UK – 20th September 2023: AccelerComm, the Layer 1 5G IP specialists, Rad...

Dr Konstantinos Leventakos Highlights the Challenge of Treatment Metastatic SCLC - Vimarsana News

Dr Konstantinos Leventakos Highlights the Challenge of Treatment Metastatic SCLC

Small cell lung cancer (SCLC) needs to be treated quickly once diagnosed, said Konstantinos Leventakos, MD, PhD, assistant professor of oncology and medicine, Mayo Clinic, Rochester, Minnesota.

Source: ajmc.com
Cancer: Know its Causes, Warning Signs, and Latest Treatment Strategies for NEET 2024 - Vimarsana News

Cancer: Know its Causes, Warning Signs, and Latest Treatment Strategies for NEET 2024

What is Cancer? It is a disease caused by the uncontrolled division of cells. This overgrowth leads to tumour formation and other physiological defects in the patient. Know more here.  

Dr Konstantinos Leventakos: Identification of Biomarkers in SCLC Is Crucial - Vimarsana News

Dr Konstantinos Leventakos: Identification of Biomarkers in SCLC Is Crucial

While some types of lung cancer have targeted therapies, there remains a need for identification of biomarkers to predict treatment response in small cell lung cancer (SCLC).

Source: ajmc.com
TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial - Vimarsana News

TAGRISSO® (osimertinib) Plus Chemotherapy Extended Median Progression-free Survival by Nearly 9 Months in EGFR-mutated Advanced Lung Cancer in FLAURA2 Phase III Trial

Combination reduced the risk of disease progression by 38% versus TAGRISSO monotherapy, the current 1st-line global standard of care ...